Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Gains from Investment Securities (2024 - 2025)

Updated

Analysis

Coherus Oncology (CHRS) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 12.61 Mn
Dec 31, 2024 4.42 Mn
Sep 30, 2024 49,000.00
Jun 30, 2024 382,000.00
Mar 31, 2024 194,000.00
API Access

Coherus Oncology Gains from Investment Securities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-investment-securities&ticker=CHRS&period=max&api_key=YOUR_API_KEY